ProKidney updates PROACT 1 enrollment target to ~470; confirmatory readout now H2 2029

PROKIDNEY CORP.

Enrollment target increased to ~470 subjects in Phase 3 PROACT 1 (REGEN-006) study.
Surrogate endpoint (eGFR slope) topline data readout still anticipated Q2 2027.
Confirmatory endpoint (composite time-to-event) topline data readout now anticipated H2 2029.
Statistical powering assumptions unchanged for both surrogate and confirmatory analyses.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.